CCL4L2 is a potential biomarker for differentiating central and peripheral vertigo

Area of Science:

• Neuroscience
• Immunology
• Genetics

Background:

• Central and peripheral vertigo present distinct pathophysiologies.
• Differentiating vertigo types requires reliable biomarkers, which are currently lacking.

Purpose of the Study:

• To investigate CCL4L2 serum expression for differentiating central and peripheral vertigo.
• To assess the diagnostic potential of CCL4L2 in vertigo patients.

Main Methods:

• Serum samples from 180 vertigo patients analyzed using RNA sequencing.
• Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis performed.
• CCL4L2 expression quantified by RT-qPCR and diagnostic accuracy evaluated via ROC curve analysis.

Main Results:

• RNA sequencing identified significant gene expression differences between central and peripheral vertigo groups.
• CCL4L2 expression was significantly elevated in central vertigo patients (p < 0.001).
• ROC analysis confirmed high diagnostic accuracy for CCL4L2 (AUC = 0.909, p < 0.001).

Conclusions:

• CCL4L2 demonstrates potential as a serum biomarker for differentiating central from peripheral vertigo.
• CCL4L2's association with inflammatory pathways suggests its role in vertigo pathogenesis.